McNeal K, Reeves K, Song P, Lapi S, Sorace A, Larimer B
Nucl Med Biol. 2024; 134-135:108918.
PMID: 38772123
PMC: 11180552.
DOI: 10.1016/j.nucmedbio.2024.108918.
Jarrett A, Song P, Reeves K, Lima E, Larimer B, Yankeelov T
Math Biosci. 2023; 366:109106.
PMID: 37931781
PMC: 10841996.
DOI: 10.1016/j.mbs.2023.109106.
Nakajima K, Sugikawa A, Yasui H, Higashikawa K, Suzuki C, Natsume T
Mol Imaging Biol. 2023; 25(4):648-658.
PMID: 37193805
DOI: 10.1007/s11307-023-01822-9.
Kniess T, Zessin J, Mading P, Kuchar M, Kiss O, Kopka K
EJNMMI Radiopharm Chem. 2023; 8(1):5.
PMID: 36897480
PMC: 10006378.
DOI: 10.1186/s41181-023-00190-7.
Liu T, Redalen K, Karlsen M
J Labelled Comp Radiopharm. 2022; 65(7):191-202.
PMID: 35466453
PMC: 9321116.
DOI: 10.1002/jlcr.3973.
Modulation of the Tumor Microenvironment with Trastuzumab Enables Radiosensitization in HER2+ Breast Cancer.
Song P, Mansur A, Lu Y, Della Manna D, Burns A, Samuel S
Cancers (Basel). 2022; 14(4).
PMID: 35205763
PMC: 8869800.
DOI: 10.3390/cancers14041015.
F-FMISO PET Imaging Identifies Hypoxia and Immunosuppressive Tumor Microenvironments and Guides Targeted Evofosfamide Therapy in Tumors Refractory to PD-1 and CTLA-4 Inhibition.
Reeves K, Song P, Angermeier A, Della Manna D, Li Y, Wang J
Clin Cancer Res. 2021; 28(2):327-337.
PMID: 34615724
PMC: 8776604.
DOI: 10.1158/1078-0432.CCR-21-2394.
Automated radiosynthesis of two F-labeled tracers containing 3-fluoro-2-hydroxypropyl moiety, [F]FMISO and [F]PM-PBB3, via [F]epifluorohydrin.
Ohkubo T, Kurihara Y, Ogawa M, Nengaki N, Fujinaga M, Mori W
EJNMMI Radiopharm Chem. 2021; 6(1):23.
PMID: 34245396
PMC: 8272768.
DOI: 10.1186/s41181-021-00138-9.
Development of Novel F-PET Agents for Tumor Hypoxia Imaging.
Wang L, Wang H, Shen K, Park H, Zhang T, Wu X
J Med Chem. 2021; 64(9):5593-5602.
PMID: 33901402
PMC: 8552308.
DOI: 10.1021/acs.jmedchem.0c01962.
Increased [F]FMISO accumulation under hypoxia by multidrug-resistant protein 1 inhibitors.
Shimizu Y, Nakai Y, Watanabe H, Iikuni S, Ono M, Saji H
EJNMMI Res. 2021; 11(1):9.
PMID: 33492449
PMC: 7835267.
DOI: 10.1186/s13550-021-00752-3.
Biodistribution and radiation dosimetry of the novel hypoxia PET probe [F]DiFA and comparison with [F]FMISO.
Watanabe S, Shiga T, Hirata K, Magota K, Okamoto S, Toyonaga T
EJNMMI Res. 2019; 9(1):60.
PMID: 31278504
PMC: 6611855.
DOI: 10.1186/s13550-019-0525-6.
Elimination of tumor hypoxia by eribulin demonstrated by F-FMISO hypoxia imaging in human tumor xenograft models.
Zhao S, Yu W, Ukon N, Tan C, Nishijima K, Shimizu Y
EJNMMI Res. 2019; 9(1):51.
PMID: 31161539
PMC: 6546772.
DOI: 10.1186/s13550-019-0521-x.
[F]FMISO PET/CT as a preoperative prognostic factor in patients with pancreatic cancer.
Yamane T, Aikawa M, Yasuda M, Fukushima K, Seto A, Okamoto K
EJNMMI Res. 2019; 9(1):39.
PMID: 31073705
PMC: 6509312.
DOI: 10.1186/s13550-019-0507-8.
Correlation between FMISO-PET based hypoxia in the primary tumour and in lymph node metastases in locally advanced HNSCC patients.
Bandurska-Luque A, Lock S, Haase R, Richter C, Zophel K, Perrin R
Clin Transl Radiat Oncol. 2019; 15:108-112.
PMID: 30834349
PMC: 6384311.
DOI: 10.1016/j.ctro.2019.02.002.
To Explore a Representative Hypoxic Parameter to Predict the Treatment Response and Prognosis Obtained by [F]FMISO-PET in Patients with Non-small Cell Lung Cancer.
Li L, Wei Y, Huang Y, Yu Q, Liu W, Zhao S
Mol Imaging Biol. 2018; 20(6):1061-1067.
PMID: 29623510
DOI: 10.1007/s11307-018-1190-2.
Changes in tumor oxygen state after sorafenib therapy evaluated by F-fluoromisonidazole hypoxia imaging of renal cell carcinoma xenografts.
Yu W, Zhao S, Zhao Y, Fatema C, Murakami M, Nishijima K
Oncol Lett. 2017; 14(2):2341-2346.
PMID: 28781672
PMC: 5530133.
DOI: 10.3892/ol.2017.6371.
FMISO accumulation in tumor is dependent on glutathione conjugation capacity in addition to hypoxic state.
Masaki Y, Shimizu Y, Yoshioka T, Nishijima K, Zhao S, Higashino K
Ann Nucl Med. 2017; 31(8):596-604.
PMID: 28695498
PMC: 5622914.
DOI: 10.1007/s12149-017-1189-9.
Quantitative evaluation of oxygen metabolism in the intratumoral hypoxia: F-fluoromisonidazole and O-labelled gases inhalation PET.
Watabe T, Kanai Y, Ikeda H, Horitsugi G, Matsunaga K, Kato H
EJNMMI Res. 2017; 7(1):16.
PMID: 28210996
PMC: 5313496.
DOI: 10.1186/s13550-017-0263-6.
Monitoring Tumor Hypoxia Using (18)F-FMISO PET and Pharmacokinetics Modeling after Photodynamic Therapy.
Tong X, Srivatsan A, Jacobson O, Wang Y, Wang Z, Yang X
Sci Rep. 2016; 6:31551.
PMID: 27546160
PMC: 4992876.
DOI: 10.1038/srep31551.
The accumulation mechanism of the hypoxia imaging probe "FMISO" by imaging mass spectrometry: possible involvement of low-molecular metabolites.
Masaki Y, Shimizu Y, Yoshioka T, Tanaka Y, Nishijima K, Zhao S
Sci Rep. 2015; 5:16802.
PMID: 26582591
PMC: 4652161.
DOI: 10.1038/srep16802.